Briacell Therapeutics CORP 8-K filings

BriaPro Therapeutics reports Q3 2026 financial results, highlighting the acquisition of sCD80 license rights and ongoing pre-clinical development.

BriaPro Therapeutics Corp. filed its unaudited interim financial statements for the period ended January 31, 2026, reporting increased losses and announcing the acquisition of an exclusive license for Soluble CD80 (sCD80) for cancer treatment, alongside a $3 million credit facility from BriaCell.

BriaCell Therapeutics Corp. successfully closed a public offering raising approximately $30 million in gross proceeds through the sale of units comprising common shares and warrants.

BriaPro Therapeutics Corp., a BriaCell subsidiary, reported significantly increased R&D expenses and operating losses for Q3 2025, highlighting its critical dependence on future financing to advance its pre-clinical oncology programs.

BriaPro Therapeutics, a BriaCell subsidiary, reported increased losses for the year ended July 31, 2025, while advancing its pre-clinical immuno-oncology programs, facing significant going concern doubts.

BriaCell Therapeutics Corp. announced a 1-for-10 reverse stock split to ensure continued compliance with Nasdaq Capital Market listing requirements.

BriaCell Therapeutics Corp., a clinical-stage biotechnology company, successfully closed a public offering raising approximately $15 million in gross proceeds through the sale of units comprising common shares and warrants.

BriaPro Therapeutics Corp., a pre-clinical immuno-oncology biotechnology company, reported significantly increased operating losses and a growing accumulated deficit for the three and nine months ended April 30, 2025, highlighting its dependence on parent company BriaCell Therapeutics Corp. and the need for future capital raises.

BriaCell Therapeutics closes a $13.8 million public offering to fund working capital and advance business objectives.

BriaPro Therapeutics Corp., a subsidiary of BriaCell Therapeutics Corp., has filed its unaudited condensed interim consolidated financial statements and management's discussion and analysis for the three and six month periods ended January 31, 2025.

BriaCell Therapeutics Corp. has received notification from Nasdaq that it has regained compliance with the minimum bid price requirement, resolving a prior non-compliance issue.

BriaCell Therapeutics Corp. held its Annual General Meeting on February 5, 2025, where shareholders elected directors and ratified the appointment of MNP LLP as auditors.

BriaCell Therapeutics Corp. successfully closed a public offering of common shares, raising $3.05 million to support working capital, corporate objectives, and the advancement of its business.

BriaCell Therapeutics Corp. has completed a 15-for-1 share consolidation to comply with Nasdaq listing requirements, effective January 24, 2025.

BriaCell Therapeutics has rescheduled its Annual General Meeting of Shareholders from January 23, 2025, to February 5, 2025, due to postal service disruptions and the need for more time to solicit proxies.

BriaCell Therapeutics Corp. has announced a 1-for-15 share consolidation to maintain compliance with Nasdaq listing requirements.

BriaPro Therapeutics, a subsidiary of BriaCell, released its unaudited financial statements for the three months ended October 31, 2024, highlighting ongoing research and development activities and a net loss.

BriaCell Therapeutics Corp. successfully closed a $5.5 million public offering of units, each consisting of one common share and one warrant.

BriaCell Therapeutics Corp. reports the resignation of Marc Lustig from its board of directors, effective November 23, 2024.

BriaPro Therapeutics Corp., a subsidiary of BriaCell, has released its financial statements for the period ended July 31, 2024, highlighting its pre-clinical research activities and AI-driven drug development strategy.

BriaCell Therapeutics Corp. has successfully priced and closed a $5 million offering of common shares and warrants, aiming to bolster working capital and advance business objectives.

BriaCell Therapeutics reports a dramatic anti-tumor response, including complete resolution of brain metastasis in a breast cancer patient treated with Bria-IMT plus an immune checkpoint inhibitor.

BriaCell Therapeutics Corp. has successfully closed an $8.5 million public offering of common shares and pre-funded warrants, priced at-the-market under Nasdaq rules.

BriaCell Therapeutics Corp. announced a poster presentation at the SITC annual meeting, positive feedback from the FDA for its prostate cancer therapy, and encouraging overall survival data for its breast cancer treatment.

BriaCell Therapeutics Corp. received a notice from Nasdaq that its share price has fallen below the minimum $1.00 requirement for continued listing.

BriaCell Therapeutics Corp. announced a significant increase in progression-free survival for a metastatic breast cancer patient treated with its Bria-IMT regimen, quadrupling the survival time compared to similar studies.

BriaCell Therapeutics Corp. received a notice from Nasdaq for failing to meet the minimum market value of listed securities requirement, granting them a 180-day compliance period to regain compliance.

BriaPro Therapeutics Corp., a subsidiary of BriaCell, has released its unaudited interim financial statements and management discussion for the three and nine months ended April 30, 2024.

BriaCell Therapeutics has announced a $5 million registered direct offering of common shares and warrants to fund working capital and research.

BriaPro Therapeutics Corp., a subsidiary of BriaCell, has released its unaudited interim financial statements for the three and six months ended January 31, 2024, following its spin-out transaction.